KR102921799B1 - 도파민 d3/d2 수용체 조절 화합물 - Google Patents

도파민 d3/d2 수용체 조절 화합물

Info

Publication number
KR102921799B1
KR102921799B1 KR1020240002897A KR20240002897A KR102921799B1 KR 102921799 B1 KR102921799 B1 KR 102921799B1 KR 1020240002897 A KR1020240002897 A KR 1020240002897A KR 20240002897 A KR20240002897 A KR 20240002897A KR 102921799 B1 KR102921799 B1 KR 102921799B1
Authority
KR
South Korea
Prior art keywords
compound
formula
present disclosure
pharmaceutically acceptable
values
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020240002897A
Other languages
English (en)
Korean (ko)
Other versions
KR20240112213A (ko
Inventor
이스트반 보르자
야노스 엘레스
발린트 멘츠진게르
데아크 실비아 보드나르네
Original Assignee
리히터 게데온 닐트.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리히터 게데온 닐트. filed Critical 리히터 게데온 닐트.
Publication of KR20240112213A publication Critical patent/KR20240112213A/ko
Priority to KR1020260017571A priority Critical patent/KR20260019592A/ko
Application granted granted Critical
Publication of KR102921799B1 publication Critical patent/KR102921799B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020240002897A 2023-01-11 2024-01-08 도파민 d3/d2 수용체 조절 화합물 Active KR102921799B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020260017571A KR20260019592A (ko) 2023-01-11 2026-01-29 도파민 d3/d2 수용체 조절 화합물

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363479530P 2023-01-11 2023-01-11
US63/479,530 2023-01-11

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020260017571A Division KR20260019592A (ko) 2023-01-11 2026-01-29 도파민 d3/d2 수용체 조절 화합물

Publications (2)

Publication Number Publication Date
KR20240112213A KR20240112213A (ko) 2024-07-18
KR102921799B1 true KR102921799B1 (ko) 2026-02-04

Family

ID=89573273

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020240002897A Active KR102921799B1 (ko) 2023-01-11 2024-01-08 도파민 d3/d2 수용체 조절 화합물
KR1020260017571A Pending KR20260019592A (ko) 2023-01-11 2026-01-29 도파민 d3/d2 수용체 조절 화합물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020260017571A Pending KR20260019592A (ko) 2023-01-11 2026-01-29 도파민 d3/d2 수용체 조절 화합물

Country Status (16)

Country Link
US (2) US12168007B1 (enExample)
EP (1) EP4400495A1 (enExample)
JP (2) JP7686096B2 (enExample)
KR (2) KR102921799B1 (enExample)
CN (2) CN122427144A (enExample)
AR (1) AR131577A1 (enExample)
AU (1) AU2024208533A1 (enExample)
CL (2) CL2025002035A1 (enExample)
CO (1) CO2025010725A2 (enExample)
GE (1) GEAP202516807A (enExample)
IL (1) IL321654A (enExample)
JO (1) JOP20250164A1 (enExample)
MX (1) MX2025008101A (enExample)
PE (1) PE20260287A1 (enExample)
TW (1) TW202432139A (enExample)
WO (1) WO2024150068A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026153547A1 (zh) * 2025-01-20 2026-07-23 上海则正医药科技股份有限公司 D3/d2受体部分激动剂及制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005012266A1 (en) * 2003-08-04 2005-02-10 Richter Gedeon Vegyészeti Gyár Rt. (thio) carbamoyl-cyclohexane derivatives as d3/d2 receptor antagonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1870405A1 (en) 2006-06-22 2007-12-26 Bioprojet Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands
HUP0800765A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts
JP5732453B2 (ja) 2009-06-25 2015-06-10 アルカーメス ファーマ アイルランド リミテッド Ｎｈ酸性化合物のプロドラッグ
WO2020156312A1 (zh) 2019-01-30 2020-08-06 江苏豪森药业集团有限公司 一种多环类衍生物调节剂、其制备方法和应用
US12617759B2 (en) 2019-10-29 2026-05-05 Shanghai Hansoh Biomedical Co., Ltd. Modifier of four-membered ring derivative, preparation method and application thereof
KR102947882B1 (ko) 2019-11-05 2026-04-03 상하이 한서 바이오메디컬 컴퍼니 리미티드 벤조티오펜 유도체 조절제, 그의 제조 방법 및 그의 용도

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005012266A1 (en) * 2003-08-04 2005-02-10 Richter Gedeon Vegyészeti Gyár Rt. (thio) carbamoyl-cyclohexane derivatives as d3/d2 receptor antagonists

Also Published As

Publication number Publication date
CL2025002035A1 (es) 2025-10-03
CN120569367A (zh) 2025-08-29
EP4400495A1 (en) 2024-07-17
CO2025010725A2 (es) 2025-08-29
JP2024098972A (ja) 2024-07-24
PE20260287A1 (es) 2026-02-10
US12168007B1 (en) 2024-12-17
TW202432139A (zh) 2024-08-16
US20250049786A1 (en) 2025-02-13
KR20260019592A (ko) 2026-02-10
WO2024150068A3 (en) 2024-08-22
GEAP202516807A (en) 2025-08-25
AU2024208533A1 (en) 2025-07-10
AR131577A1 (es) 2025-04-09
JP7686096B2 (ja) 2025-05-30
JP2025122072A (ja) 2025-08-20
MX2025008101A (es) 2025-08-01
CL2026000558A1 (es) 2026-06-05
JOP20250164A1 (ar) 2025-07-10
IL321654A (en) 2025-08-01
KR20240112213A (ko) 2024-07-18
WO2024150068A2 (en) 2024-07-18
CN122427144A (zh) 2026-07-21

Similar Documents

Publication Publication Date Title
KR20260019592A (ko) 도파민 d3/d2 수용체 조절 화합물
US6586435B2 (en) Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors
JP5437473B2 (ja) Ａｍｐａ及びｎｍｄａ受容体モジュレーターとして使用するベンゾチアジアゼピン誘導体
DE69331688T2 (de) Pyridopyrimidinderivate, ihre Herstellung und Verwendung
EP1235798A1 (en) 1,4 substituted piperidinyl nmda/nr2b antagonists
EP1116722B1 (en) [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES
EP1100795B1 (de) Disubstituierte bicyclische heterocyclen mit insbesondere eine thrombinhemmende wirkung
AU718748B2 (en) AZA and AZA (N-oxy) analogs of glycine/NMDA receptor antagonists
Van der Walt et al. 1, 3, 7-Triethyl-substituted xanthines—possess nanomolar affinity for the adenosine A1 receptor
DE4332168A1 (de) Cyclische Derivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US10568885B2 (en) (4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-y1)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-citrate
CA2417082C (en) New benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors
US8299098B2 (en) Piperidinyl derivative as a modulator of chemokine receptor activity
DE1795022B2 (enExample)
US5182279A (en) Benzothienopyrazinedione compounds and their preparation and use
HK40114011A (en) Dopamine d3/d2 receptor modulating compounds
US6602865B1 (en) Pyridazino(4,5-b)(1,5)oxazepinone, -thiazepinone and -diazepinone compounds
JP6833852B2 (ja) 結晶形
KR20250053174A (ko) 신경계 장애의 치료를 위한 헤테로방향족 화합물
Hauke et al. Generation and screening of pseudostatic hydrazone libraries derived from 5-substituted nipecotic acid derivatives at the GABA transporter mGAT4
Catarzi et al. Pharmacological characterization of some selected 4, 5-dihydro-4-oxo-1, 2, 4-triazolo [1, 5-a] quinoxaline-2-carboxylates and 3-hydroxyquinazoline-2, 4-diones as (S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)-propionic acid receptor antagonists
DE60022316T2 (de) 6-substituierte 7-heterochinoxalin-carbonsäure- derivate und ihre additionssalze und verfahren zur herstellung von beiden
US5484793A (en) Compounds derived from 6-azaindoles as ligands of the benzodiazepine receptor and medicaments containing them
FI88036C (fi) Foerfarande foer framstaellning av saosom bensodiazepinreceptoragonister/antagonister anvaendbara 2-aryl-tetrahydro(pyrido- och pyrrolo)/e//1,2,4/triazolo/1,5-c/pyrimidoner
Soo-Jin et al. Antihistamine activities of iminodiacetamide derivatives

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0107 (AS PROVIDED BY THE NATIONAL OFFICE)

A18 Application divided or continuation or continuation in part accepted

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A18-DIV-PA0107 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0107 Divisional application

St.27 status event code: A-0-1-A10-A18-div-PA0107

St.27 status event code: A-0-1-A10-A16-div-PA0107

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)